# ResMed Inc. (RMD) FY2027 Q1 Statement of Cash Flows

- Company: ResMed Inc. (RMD)
- Period: 2026-07-01 to 2026-09-30
- Filing: Q1 FY2027 10-Q, filed 2026-10-30, accession number 0000943819-26-000089
- Page: https://plicit.ai/financials/rmd/fy2027-q1-cash-flow
- Chart image: https://plicit.ai/charts/rmd-fy2027-q1-cash-flow-sankey.png

## Chart details

Cash flows for Jul 1, 2026 through Sep 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Jun 30, 2026. Ending cash: Sep 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

- **Beginning cash on Jun 30, 2026**: 1,469,234,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
- **Operating activities**: 422,422,000 US dollars. Net cash provided.
- **Net income**: 418,413,000 US dollars
- **Depreciation and amortization**: 41,741,000 US dollars
- **Amortization of right-of-use assets**: 10,090,000 US dollars
- **Stock-based compensation costs**: 29,475,000 US dollars
- **(Gain) loss attributable to equity method investments**: negative 1,884,000 US dollars
- **(Gain) loss on equity investments**: negative 5,719,000 US dollars
- **Accounts receivable, net**: 64,839,000 US dollars
- **Inventories**: negative 71,764,000 US dollars
- **Prepaid expenses, net deferred income taxes and other current assets**: negative 69,988,000 US dollars
- **Accounts payable, accrued expenses, income taxes payable and other**: 62,761,000 US dollars
- **(Gain) loss on divestment of subsidiaries**: negative 61,784,000 US dollars
- **Non-cash restructuring expenses**: 6,242,000 US dollars
- **Investing activities**: 392,055,000 US dollars. Net cash provided.
- **Purchases of property, plant and equipment**: negative 48,740,000 US dollars
- **Patent registration and acquisition costs**: negative 2,432,000 US dollars
- **Business acquisitions, net of cash acquired**: negative 7,487,000 US dollars
- **Purchases of investments**: negative 2,721,000 US dollars
- **Proceeds (payments) on maturity of foreign currency contracts**: 2,615,000 US dollars
- **Proceeds from divestment of subsidiaries, net of cash divested**: 450,820,000 US dollars
- **Financing activities**: negative 1,278,003,000 US dollars. Net cash used.
- **Proceeds from issuance of common stock, net**: 3,654,000 US dollars
- **Taxes paid related to net share settlement of equity awards**: negative 325,000 US dollars
- **Purchases of treasury stock**: negative 936,378,000 US dollars
- **Repayment of borrowings**: negative 250,000,000 US dollars
- **Dividends paid**: negative 94,954,000 US dollars
- **Operating adjustment reconciliation**: 215,148,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
- **financing gross reconciliation**: 1,281,657,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- **investing gross reconciliation**: 453,435,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- **Exchange-rate effect**: 5,034,000 US dollars
- **Ending cash on Sep 30, 2026**: 1,010,742,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
- **Cash sources and uses**: 2,288,745,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
- **Net cash change**: negative 458,492,000 US dollars. Ending cash minus beginning cash.
- **Cash flow / Net income**: 1.01×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
- **Operating cash flow**: 422,422,000 US dollars. Operating cash flow used in the free cash flow calculation.
- **Cash purchases of property, plant and equipment**: 48,740,000 US dollars. These cash purchases are already included in investing activities above.
- **Free cash flow**: 373,682,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

### Chart connections

- Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
- Financing contributions meet at a reconciliation junction before connecting to the net cash total.
- Investing contributions meet at a reconciliation junction before connecting to the net cash total.
- Operating reconciliation adjustments are not all independent cash receipts.
- Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $4.01M after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
- Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
- The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
- Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 422,422,000 US dollars minus 48,740,000 US dollars equals 373,682,000 US dollars.

## Key Takeaways

- Operating cash fell $34.90 M to $422.42 M, even as profit rose $69.88 M.
- Share buybacks of $936.38 M dwarfed the $94.95 M in dividends and $250.00 M of debt repaid.
- Cash after capital spending, $373.68 M, covered 36% of the $1.03 B paid out.
- The share count fell 2.4% in a year, but the buyback cost $936.38 M in cash this quarter.
- Inventories took $71.76 M of cash, and finished goods rose $72.08 M in the quarter.

## The Unvarnished Truth

### ResMed paid shareholders $1.03 B, 2.8 times its free cash.

ResMed's cash from operations, the money its everyday business brings in once its bills are paid, fell $34.90 M to $422.42 M, even as profit rose $69.88 M. That gap is the first alarm. The bigger one is what came next: ResMed paid out $1.03 B to its shareholders, a sum 2.8 times the $373.68 M it kept after spending on equipment. Cash from operations is the figure to watch, because it shows what the business produced in cash before any sale of assets.

Where did the money go? Purchases of treasury stock, the company's own shares, came to $936.38 M. Management ties the jump to buybacks, and it says the year-earlier figure was $150 million. A $450 million accelerated buyback agreement was paid in part from the MatrixCare sale, which the cash table books as $450.82 M of investing cash, not as operating cash. Debt is the other drain: ResMed repaid $250.00 M of its 3.24% senior notes, which were repaid in full on July 10, 2026.

Put together, ResMed kept $373.68 M after capital spending and sent $1.03 B to shareholders in one quarter, which is why its cash fell $458.49 M to $1.01 B. The filing says working capital drove the drop in operating cash, with inventory the biggest piece. The accelerated buyback still has to settle by December 29, 2026, which keeps the drain running into the next quarter. Will the finished goods sell through before the next buyback draws on the same cash pile?

## Intelligent Insights for Investors

### Is ResMed bringing in more cash from operations than a year ago?

No: cash from operations, the cash its everyday business brings in once its bills are paid, came to $422.42 M this quarter, $34.90 M lower than a year earlier. Over the same span, profit, what is left after every cost, interest charge and tax, plus any gains on the side, rose $69.88 M.

### Did free cash cover dividends and buybacks?

No: dividends and buybacks took $1.03 B this quarter, more than the $373.68 M left after spending on property and equipment. Its cash balance fell over the same period.

### Are buybacks actually reducing the share count?

The share count is falling. ResMed spent $936.38 M buying back shares this quarter, and its average diluted share count was down 2.4% from a year earlier, at 143 million shares.

## Intelligent Insights for Lenders

### Is ResMed borrowing more or paying down debt?

ResMed is paying debt down: repayments beat new borrowing by $250.00 M this quarter, where a year earlier it had no net borrowing. The company repaid its 3.24% senior notes in full on July 10, 2026, and had $410 M outstanding at quarter end.

## Intelligent Insights for Employees

### How much does ResMed pay its people in stock instead of cash?

ResMed paid its people $29.48 M in stock this quarter, equal to 2.1% of sales and 7.0% of its cash from operations. Because the pay is in shares, the expense is added back to get cash from operations.

## Intelligent Insights for Suppliers

### Did ResMed slow its inventory purchases from suppliers?

No: it bought more than it sold. Purchases implied by cost of sales and the change in inventory came to $619.80 M this quarter, 14% above its $544.25 M cost of sales, as inventory grew.
